Research Studies
Elevate-PD
Criteria
About this study
The main purpose of this study is to see how effective and safe CREXONT® is for people with Parkinson’s disease (PD) in everyday life. CREXONT is a combination of levodopa (LD) and carbidopa (CD) used to treat PD. It was approved by the Food and Drug Administration (FDA) in August 2024.